Business Context and Reporting Period
This Form 8-K Current Report was filed by CRISPR Therapeutics AG on December 21, 2017, regarding events occurring on December 20, 2017. The filing addresses significant changes in corporate governance, specifically the departure of the Chairman of the Board and the appointment of a new Chairman, alongside the formalization of an employment agreement for the President.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation arrangements and board composition changes.
Material Changes
- Director Departure: Dr. Anthony Coles resigned as a director and Chairman of the Board effective December 20, 2017. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Advisory Role: Dr. Coles entered into an Advisory Agreement to provide services on strategic and operational matters (e.g., financing, partner management) on an hourly basis. The initial term expires on September 10, 2019, with options for six-month renewals.
- Chairman Appointment: Dr. Rodger Novak, a current board member, was appointed Chairman of the Board effective December 20, 2017, serving until the next ordinary shareholder meeting.
- Executive Compensation Update: An Employment Agreement was formalized for Dr. Rodger Novak (President), effective December 1, 2017.
- Salary: Annual base salary remains unchanged through November 30, 2018. Starting December 1, 2018, the annual base salary is set at $125,000, subject to yearly adjustments.
- Bonuses: Dr. Novak is eligible for a fiscal year 2017 bonus. He is not eligible for future bonuses for fiscal year 2018 and thereafter unless otherwise agreed by the Board.
- Equity Vesting: Unvested equity awards granted prior to the effective date will continue to vest through November 30, 2018. Thereafter, the vesting rate for remaining unvested awards will be reduced to 50% of the original schedule, with the timeline extended accordingly.
- Termination: The agreement allows for termination for convenience with two months' written notice on or after December 1, 2018. Full vesting of unvested awards occurs if employment is terminated prior to December 1, 2018, within 18 months of a Change in Control.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It notes that the information regarding the press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific hourly rate and scope of services in the Advisory Agreement with Dr. Anthony Coles (Exhibit 10.1).
- Review the full Employment Agreement with Dr. Rodger Novak (Exhibit 10.2) to understand the precise definitions of "good cause" and "Change in Control."
- Confirm the impact of the reduced equity vesting schedule (50% rate post-November 2018) on Dr. Novak's total compensation package.
- Monitor the Company's next ordinary shareholder meeting for the confirmation of Dr. Novak's continued tenure as Chairman.